Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype
Introduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2019-12-01
|
Series: | Endocrine Connections |
Subjects: | |
Online Access: | https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xml |
id |
doaj-72a03e609bec496c9e62c8012b2c040a |
---|---|
record_format |
Article |
spelling |
doaj-72a03e609bec496c9e62c8012b2c040a2020-11-25T02:07:51ZengBioscientificaEndocrine Connections2049-36142049-36142019-12-0181216001606https://doi.org/10.1530/EC-19-0372Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtypeB C M Hermans0J L Derks1H J M Groen2J A Stigt3R J van Suylen4L M Hillen5E C van den Broek6E J M Speel7A-M C Dingemans8Department of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, University of Groningen and University Medical Centre, Groningen, The NetherlandsDepartment of Pulmonary Diseases, Isala Hospital, Zwolle, The NetherlandsPathology-DNA, Jeroen Bosch Hospital, ‘s Hertogenbosch, The NetherlandsDepartment of Pathology, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsPALGA Foundation, Utrecht, The NetherlandsDepartment of Pathology, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsDepartment of Pulmonary Diseases, GROW School for Oncology & Developmental Biology, Maastricht University Medical Centre, Maastricht, The NetherlandsIntroduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up. Methods: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1). Results: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI wa s 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found. Conclusion: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype. https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xmllarge cell neuroendocrine carcinomalcnecsolitary brain metastasisprognosiski-67 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
B C M Hermans J L Derks H J M Groen J A Stigt R J van Suylen L M Hillen E C van den Broek E J M Speel A-M C Dingemans |
spellingShingle |
B C M Hermans J L Derks H J M Groen J A Stigt R J van Suylen L M Hillen E C van den Broek E J M Speel A-M C Dingemans Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype Endocrine Connections large cell neuroendocrine carcinoma lcnec solitary brain metastasis prognosis ki-67 |
author_facet |
B C M Hermans J L Derks H J M Groen J A Stigt R J van Suylen L M Hillen E C van den Broek E J M Speel A-M C Dingemans |
author_sort |
B C M Hermans |
title |
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_short |
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_full |
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_fullStr |
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_full_unstemmed |
Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype |
title_sort |
large cell neuroendocrine carcinoma with a solitary brain metastasis and low ki-67: a unique subtype |
publisher |
Bioscientifica |
series |
Endocrine Connections |
issn |
2049-3614 2049-3614 |
publishDate |
2019-12-01 |
description |
Introduction: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40–80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small-cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small-cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up.
Methods: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next-generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1).
Results: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5–18.5 months). Mean Ki-67 PI wa s 59% (range 15–100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11–23 months) vs 5 months (95% CI 0.7–9 months), P = 0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified, and both SCLC-like (n = 6) and NSCLC-like (n = 2) subtypes were present. No MEN1 mutation was found.
Conclusion: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.
|
topic |
large cell neuroendocrine carcinoma lcnec solitary brain metastasis prognosis ki-67 |
url |
https://ec.bioscientifica.com/view/journals/ec/aop/ec-19-0372/ec-19-0372.xml |
work_keys_str_mv |
AT bcmhermans largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT jlderks largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT hjmgroen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT jastigt largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT rjvansuylen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT lmhillen largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT ecvandenbroek largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT ejmspeel largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype AT amcdingemans largecellneuroendocrinecarcinomawithasolitarybrainmetastasisandlowki67auniquesubtype |
_version_ |
1724929199548923904 |